These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32710973)

  • 1. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
    Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
    J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential strategies for combating COVID-19.
    Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
    Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukotrienes, a potential target for Covid-19.
    Citron F; Perelli L; Deem AK; Genovese G; Viale A
    Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
    [No Abstract]   [Full Text] [Related]  

  • 4. Audio Interview: New Data on Remdesivir in Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
    [No Abstract]   [Full Text] [Related]  

  • 5. Early experience with remdesivir in SARS-CoV-2 pneumonia.
    Durante-Mangoni E; Andini R; Bertolino L; Mele F; Florio LL; Murino P; Corcione A; Zampino R
    Infection; 2020 Oct; 48(5):779-782. PubMed ID: 32418190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating COVID-19 with colchicine in community healthcare setting.
    Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
    Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
    [No Abstract]   [Full Text] [Related]  

  • 10. Covid-19: Time for a paradigm change.
    Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
    Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
    [No Abstract]   [Full Text] [Related]  

  • 11. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
    Barlow A; Landolf KM; Barlow B; Yeung SYA; Heavner JJ; Claassen CW; Heavner MS
    Pharmacotherapy; 2020 May; 40(5):416-437. PubMed ID: 32259313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
    Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
    Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
    [No Abstract]   [Full Text] [Related]  

  • 14. Liver injury in remdesivir-treated COVID-19 patients.
    Zampino R; Mele F; Florio LL; Bertolino L; Andini R; Galdo M; De Rosa R; Corcione A; Durante-Mangoni E
    Hepatol Int; 2020 Sep; 14(5):881-883. PubMed ID: 32725454
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
    Moutsopoulos HM
    Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
    [No Abstract]   [Full Text] [Related]  

  • 16. Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective.
    Mansuri Z; Shah B; Zafar MK; Jolly T; Jain S
    Prim Care Companion CNS Disord; 2020 May; 22(3):. PubMed ID: 32470232
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 18. Lessons from the Italian COVID-19 frontline.
    Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM
    Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
    Magro G
    Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.